Cervical Cancer

CERVARIX(R) U.S. Regulatory Update
GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18. GSK has submitted final data from its Phase III pivotal efficacy study, HPV-008, to the FDA. The FDA has previously reviewed interim data from the same trial.